MARKET

VKTX

VKTX

Viking Therapeutics Inc
NASDAQ
31.65
+0.95
+3.08%
Opening 15:50 07/16 EDT
OPEN
31.35
PREV CLOSE
30.70
HIGH
31.94
LOW
30.67
VOLUME
2.19M
TURNOVER
--
52 WEEK HIGH
81.73
52 WEEK LOW
18.92
MARKET CAP
3.55B
P/E (TTM)
-27.4768
1D
5D
1M
3M
1Y
5Y
1D
B.Riley Financial Sticks to Its Buy Rating for Viking Therapeutics (VKTX)
TipRanks · 15h ago
Weekly Report: what happened at VKTX last week (0707-0711)?
Weekly Report · 2d ago
Terns Pharmaceuticals: A Risky Buy Ahead Of Q4 Obesity, Oncology Catalysts
Seeking Alpha · 5d ago
Can Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?
NASDAQ · 5d ago
VKTX August 29th Options Begin Trading
NASDAQ · 6d ago
Lilly Down More Than 15% in a Year: Time to Buy, Sell or Hold?
NASDAQ · 6d ago
Viking Therapeutics: What's Next After GLP-1 Hype Dies Down And Competition Intensifies
Seeking Alpha · 6d ago
Is Novo Nordisk Increasing Dosage to Defend Wegovy's Edge in Obesity?
NASDAQ · 07/09 15:48
More
About VKTX
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for the treatment of metabolic and endocrine disorders. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. It is evaluating an oral formulation of VK2735 in a Phase II trial. It is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.

Webull offers Viking Therapeutics Inc stock information, including NASDAQ: VKTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VKTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VKTX stock methods without spending real money on the virtual paper trading platform.